SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-016524
Filing Date
2022-06-13
Accepted
2022-06-13 09:32:04
Documents
17
Period of Report
2022-06-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 53093
2 ex10-1.htm EX-10.1 312393
3 ex10-2.htm EX-10.2 40852
4 ex10-3.htm EX-10.3 39379
5 ex99-1.htm EX-99.1 24522
6 ex99-1_001.jpg GRAPHIC 3113
  Complete submission text file 0001493152-22-016524.txt   742824

Data Files

Seq Description Document Type Size
7 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prph-20220610.xsd EX-101.SCH 2971
8 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prph-20220610_lab.xml EX-101.LAB 34240
9 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prph-20220610_pre.xml EX-101.PRE 22367
11 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3607
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 221010855
SIC: 2834 Pharmaceutical Preparations